Pryor Cashman represented Nastech Pharmaceutical Co. in the negotiation of a manufacturing and supply agreement with Procter & Gamble for parathyroid hormone (PTH1-34) nasal spray.

Under the agreement announced June 6, 2006, Nastech will manufacture and supply PTH1-34 nasal spray for the potential commercialization of this investigational product for the treatment of osteoporosis. Nastech also will be responsible for the chemistry, manufacturing and controls sections of the Food & Drug Administration regulatory submission.

Nastech (www.nastech.com) is a pharmaceutical company developing innovative products based on proprietary, molecular biology-based drug delivery technologies. Nastech and its collaboration partners are developing products for multiple therapeutic areas including respiratory disease, inflammatory conditions, obesity and osteoporosis.

The Pryor Cashman team working on this transaction included partners Stephen Goodman and Larry Remmel.